Disease relevance of RPL6

• RPL6 was mapped to chromosome 12q24.1 between the markers D12S84 and D12S861, which is in the critical region for Noonan syndrome [1].
• Together, this work demonstrates that RPL6 could regulate MDR in gastric cancer cells by suppressing drug-induced apoptosis [2].
• L6/TAXREB107 also mediates the DNA binding of the HTLV-1 transactivator Tax [3].
• Paroxysmal nocturnal hemoglobinuria: Differential gene expression of EGR-1 and TAXREB107 [4].
• Using a subtractive hybridization strategy, we have identified the murine homolog of the TAX response element-binding protein TAXREB107 as an Epo early response gene in Rauscher murine erythroleukemia cells [5].

High impact information on RPL6

• Sequence of a cDNA encoding human ribosomal protein L26 and of a cDNA probably encoding human ribosomal protein L6 [6].
• In contrast, significant upregulation of TAXREB107 is present only in some of our PNH patients [4].
• These results suggest that the Xq28-linked gene is a processed pseudogene for TXREB and that the previously reported cDNA was only partially processed [7].
• The results implicate TAXREB107 in erythropoiesis and support the hypothesis that the TAXREB proteins have functions outside the context of HTLV-I infection [5].
• In vitro binding experiments indicated that both the high-molecular-weight forms (HMW) and the 18-kDa form of FGF-2 bind to L6/TAXREB107 [3].

Biological context of RPL6

• RPL6 spans 4415bp and consists of seven exons and six introns [1].
• One of the three cDNAs, encoding TAXREB107, contained an open reading frame with 288 amino acid residues [8].
• Isolation of a cDNA clone encoding DNA-binding protein (TAXREB107) that binds specifically to domain C of the tax-responsive enhancer element in the long terminal repeat of human T-cell leukemia virus type I [8].
• Upregulation of RPL6 was associated with enhanced resistance to multiple anticancer drugs (adriamycin, vincristine, etoposide, 5-fluorouracil and cisplatin) and to adriamycin-induced apoptosis [2].
• By gene transfection, RPL6 was genetically upregulated in SGC7901 or down-regulated in SGC7901/ ADR cells [2].

Anatomical context of RPL6

• Immunoblot analysis showed that polyclonal antibody against TAXREB107 specifically recognized a 34-kD protein in Jurkat cells [8].

Associations of RPL6 with chemical compounds

• Alteration of RPL6 showed no obvious influence on intracellular adriamycin accumulation, glutathione content and expression of glutathione S-transferase [2].

Other interactions of RPL6

• Intracellular association of FGF-2 with the ribosomal protein L6/TAXREB107 [3].
• The aim of this study was to explore the roles of RPL6 in multidrug resistance (MDR) in gastric cancer cells [2].
• RESULTS: Expression of two of these genes, EGR-1 and TAXREB107, has been further investigated [4].

Analytical, diagnostic and therapeutic context of RPL6

• We have refined the position of RPL6, using two different radiation hybrid panels [1].
• Northern and Western blot analysis confirmed that RPL6 was overexpressed in SGC7901/ADR cells [2].
• Southern blot analysis on a hybrid mapping panel confirmed the presence of at least one autosomal gene for TXREB, and Northern blot hybridization with the 599-bp putative intron probe confirmed that the sequence is not part of the mature mRNA [7].
• Ribosomal protein L6, ribosomal protein S7, chaperonin 10, and cytochrome oxidase I were identified to be up-regulated 4- to 5-fold after 70% partial hepatectomy [9].

References